The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Minocycline Development for Acute Ischemic Stroke
Open accessAbstract
Minocycline, a tetracycline antibiotic, has shown anti-inflammatory, anti-apoptotic, and neuroprotective effects in many models of cerebral ischemia and neurodegenerative disease. Its high penetration of the blood-brain barrier, good safety profile, and delayed therapeutic window make it an ideal candidate for use in stroke. In animal models, minocycline reduced infarct size and improved neurologic outcome when administered acutely, with similar neuroprotective benefits seen following delayed administration. To date, two early phase clinical trials have shown minocycline to be safe and potentially effective in acute ischemic stroke, alone or in combination with tissue plasminogen activator. A large efficacy clinical trial is now needed to confirm previous studies, allow for subgroup analysis, and pinpoint the potential place for minocycline in acute stroke therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“So far, minocycline has been incorporated into two clinical trials involving ischemic stroke patients, demonstrating that minocycline administration (both alone and in combination with Fibrinolysis) improved neurological functional outcome following stroke (Fagan et al., 2011).”
From The impact of microglial activation on blood-brain barrier in brain diseases (2014) · cites this paper as Fagan et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183
Zhu, S., Stavrovskaya, I. G., Drozda, M., Kim, B. Y. S., Ona, V. O., Li, M., Sarang, S. S., Liu, A. S., Hartley, D. M., Wu, D. C., et al. (2002) · Nature · doi:10.1038/417074a · Cited by 1,069
Chen, M., Ona, V. O., Li, M., Ferrante, R. J., Fink, K., Zhu, S., Bian, J., Guo, L., Farrell, L. A., Hersch, S. M., et al. (2000) · Nature Medicine · doi:10.1038/77528 · Cited by 1,060
Yrjänheikki, J., Kauppinen, T. M., Keinänen, R., Goldsteins, G., Chan, P. H., & Koıstınaho, J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13496 · Cited by 1,040
Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia
Yrjänheikki, J., Keinänen, R., Pellikka, M., Hökfelt, T., & Koistinaho, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15769 · Cited by 1,006
Tikka, T., Fiebich, B. L., Goldsteins, G., Keinänen, R., & Koistinaho, J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-08-02580.2001 · Cited by 958
Clinical interpretation and use of stroke scales
Kasner, S. E. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70495-1 · Cited by 947
Du, Y., Ma, Z., Lin, S., Dodel, R. C., Gao, F., Bales, K. R., Triarhou, L. C., Chernet, E., Perry, K. W., Nelson, D. L. G., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251341998 · Cited by 789
Matrix Metalloproteinases Increase Very Early during Experimental Focal Cerebral Ischemia
Heo, J. H., Lucero, J. D., Abumiya, T., Koziol, J. A., Copeland, B. R., & del Zoppo, G. J. (1999) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199906000-00005 · Cited by 547
Minocycline treatment in acute stroke
Lampl, Y., Boaz, M., Gilad, R., Lorberboym, M., Dabby, R., Rapoport, A. M., Anca-Hershkowitz, M., & Sadeh, M. (2007) · Neurology · doi:10.1212/01.wnl.0000277487.04281.db · Cited by 452
Cited by
Sorted by citations
Items 101–102 of 102
Khalid, S., Abbas, M. A. A., Shahid, M. S., Malik, M. N. M. A., Javed, M., Rehman, A., Ashraf, S., Tariq, M. D., & Rai, D. (2026) · Brain and Behavior · doi:10.1002/brb3.71576
Matrix Metalloproteinases as an Inflammatory Mediator in the Neurovascular Unit
Xing, C., Maki, T., Seo, J. H., Arai, K., & Lo, E. H. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8915-3_6
Metadata
- Authors
- Fagan, S. C., Cronic, L. E., & Hess, D. C.
- Affiliations
- University of Georgia (US)
- Corresponding author
- Fagan, Susan C.
- ORCID
- Hess, David C.
- Venue
- Translational Stroke Research
- Published
- 2011-04-13
- Volume
- 2
- Issue
- 2
- Pages
- 202-208
- ISSN
- 1868-4483 (ISSN-L)
- 1868-601X
- PMC
- PMC3169090
- OpenAlex
- W2019475666
- Cited by
- 100
- References
- 53
- Citations by year
- 2026: 2 · 2024: 5 · 2023: 6 · 2022: 7 · 2021: 3 · 2020: 9 · 2019: 5 · 2018: 8 · 2017: 6 · 2016: 7 · 2015: 8 · 2014: 7 · 2013: 15 · 2012: 10
- FWCI
- 8.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Translational Stroke Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (R01NS063965, R01NS055728)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- minocycline, acute ischemic stroke, neuroprotection, anti-inflammatory activity, anti-apoptotic effects, blood-brain barrier penetration, infarct size, tissue plasminogen activator, clinical trials, drug development
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
